tirzepatide-weight management 2.5 mg/0.5ml solution auto-injector Zepbound Tirzepatide Injection mg/0.5 mL tirzepatide (weight loss) 7.5 mg/0.5

Clin Hypertens

Demographic Groups Leading GLP-1 Weight Loss Medication Growth Women comprise approximately 65 percent of GLP-1 medication users, reflecting higher engagement with weight management and willingness to pursue pharmacologic interventions alongside lifestyle changes

Asia Pacific, accounting for 23.4% of global revenue in 2025, is the fastest-growing region at a projected CAGR of 18.9% through 2034, driven by China's 140 million-plus diabetic population and India's emerging role as both a major end-market and semaglutide API production hub

A review of practical issues on the use of glucagon-like peptide-1 receptor agonists for the management of type 2 diabetes